Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Trace Amine Associated Receptor 1 (TAAR1) Agonist 2-(5-(4'-Chloro-[1,1'-biphenyl]-4-yl)-4H-1,2,4-triazol-3-yl)ethan-1-amine (LK00764) for the Treatment of Psychotic Disorders.
Krasavin M, Lukin A, Sukhanov I, Gerasimov AS, Kuvarzin S, Efimova EV, Dorofeikova M, Nichugovskaya A, Matveev A, Onokhin K, Zakharov K, Gureev M, Gainetdinov RR. Krasavin M, et al. Among authors: zakharov k. Biomolecules. 2022 Nov 7;12(11):1650. doi: 10.3390/biom12111650. Biomolecules. 2022. PMID: 36359001 Free PMC article.
Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders.
Krasavin M, Peshkov AA, Lukin A, Komarova K, Vinogradova L, Smirnova D, Kanov EV, Kuvarzin SR, Murtazina RZ, Efimova EV, Gureev M, Onokhin K, Zakharov K, Gainetdinov RR. Krasavin M, et al. Among authors: zakharov k. Int J Mol Sci. 2022 Sep 30;23(19):11579. doi: 10.3390/ijms231911579. Int J Mol Sci. 2022. PMID: 36232878 Free PMC article.
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts.
Gordeychuk IV, Kozlovskaya LI, Siniugina AA, Yagovkina NV, Kuzubov VI, Zakharov KA, Volok VP, Dodina MS, Gmyl LV, Korotina NA, Theodorovich RD, Ulitina YI, Vovk DI, Alikova MV, Kataeva AA, Kalenskaya AV, Solovjeva IV, Tivanova EV, Kondrasheva LY, Ploskireva AA, Akimkin VG, Subbotina KA, Ignatyev GM, Korduban AK, Shustova EY, Bayurova EO, Zhitkevich AS, Avdoshina DV, Piniaeva AN, Kovpak AA, Antonova LP, Rogova YV, Shishova AA, Ivin YY, Sotskova SE, Chernov KA, Ipatova EG, Korduban EA, Ishmukhametov AA. Gordeychuk IV, et al. Among authors: zakharov ka. Viruses. 2023 Aug 29;15(9):1828. doi: 10.3390/v15091828. Viruses. 2023. PMID: 37766235 Free PMC article. Clinical Trial.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaia TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zubkova TG, Zakharov KA, Vasilyuk VB, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Lancet Reg Health Eur. 2021 Dec;11:100241. doi: 10.1016/j.lanepe.2021.100241. Epub 2021 Nov 2. Lancet Reg Health Eur. 2021. PMID: 34746910 Free PMC article.
Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine.
Rabdano S, Ruzanova E, Makarov D, Vertyachikh A, Teplykh V, Rudakov G, Pletyukhina I, Saveliev N, Zakharov K, Alpenidze D, Vasilyuk V, Arakelov S, Skvortsova V. Rabdano S, et al. Among authors: zakharov k. Vaccines (Basel). 2024 Jan 19;12(1):100. doi: 10.3390/vaccines12010100. Vaccines (Basel). 2024. PMID: 38276672 Free PMC article.
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study.
Belogurov A Jr, Zakharov K, Lomakin Y, Surkov K, Avtushenko S, Kruglyakov P, Smirnov I, Makshakov G, Lockshin C, Gregoriadis G, Genkin D, Gabibov A, Evdoshenko E. Belogurov A Jr, et al. Among authors: zakharov k. Neurotherapeutics. 2016 Oct;13(4):895-904. doi: 10.1007/s13311-016-0448-0. Neurotherapeutics. 2016. PMID: 27324388 Free PMC article. Clinical Trial.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
47 results